23-1243m Medical Policies - September 2023
Date: 10/30/23
Check out the new policies and the latest changes to existing medical policies for procedures and services
The medical policies listed in this update were approved for September 2023. These policies may apply to CalViva Health members if there are no available medical policies from the California Department of Health Care Services. For a complete description of the background, criteria, references, and coding implications for the medical policies, go to Medical Policies.
Purpose of medical policies
Medical policies offer guidelines to help determine medical necessity for certain procedures, equipment and services. They are not intended to give medical advice or tell providers how to practice. If required, providers must get prior authorization before services are given.
Medical policies vs. member contract
All services must be medically needed unless the member’s benefit plan coverage document states otherwise. This document defines member benefits in addition to eligibility requirements, and coverage exclusions and limits.
- For Medi-Cal plans, appropriate coverage guidelines take precedence over these plan policies and must be applied first.
- If legal or regulatory mandates apply, they may override medical policy.
- If there are any conflicts between medical policy guidelines and related member benefits contract language, the benefits contract will apply.
New Policies
Medical policy | Policy statement |
|---|---|
CP.MP.250 – Lantidra (donislecel) Allogenic Pancreatic Islet Cellular Therapy | This policy describes the medical necessity criteria for Lantidra (donislecel), an allogeneic pancreatic islet cellular therapy, used for the treatment of type 1 diabetes in those who are unable to reach target hemoglobin A1c (HbA1c). |
HNCA.CP.MP.679 – Palliative Care Eligibility Criterial | This policy describes eligibility criteria for adult and pediatric members. |
Updated Policies
Policy number and name | Change |
|---|---|
CP.MP.101 – Donor Lymphocyte Infusion | Updated all criteria in statements I. and II. |
CP.MP.248 – Facility-Based Sleep Studies for Obstructive Sleep Apnea | Corrected I.B.8.a.i. to require either continuous, chronic nocturnal oxygen use or moderate to severe pulmonary function impairment instead of both. |
CP. MP.69 – Intensity-Modulated Radiotherapy |
|
CP.MP.57 – Lung Transplantation | Revised adult and pediatric criteria to align with International Society for Heart and Lung Transplantation (ISHLT) 2021 consensus document. |
CP.MP.246 – Pediatric Kidney Transplant |
|
CP.MP.133 – Posterior Nerve Stimulation for Voiding Dysfunction | Revised policy statement and all criteria verbiage in Criteria I. |
CP.MP. 166 – Sacroiliac Joint Interventions for Pain Management |
|
Inactive policies
The following policies have been retired:
Policy number | Policy name |
|---|---|
N/A | ADHD Clinical Practice Guideline |
CP.MP.158 | Ambulatory Surgery Center Optimization |
Additional information
If you have questions regarding the information contained in this update, contact CalViva Health at 888-893-1569.
This information applies to Physicians, Participating Physician Groups (PPGs), Hospitals, and Ancillary providers.
This information applies to Medi-Cal in Fresno, Kings and Madera counties.